JSJuan Shi

Juan Shi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Juan Shi has a total of 117 co-authors. Here are the top co-authors by number of shared publications:

  • Yifei Zhang

    Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, China

    10 shared publications
  • Weiqing Wang

    Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

    8 shared publications
  • Ying Peng

    Department of Endocrine and Metabolic Diseases Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai China

    8 shared publications
  • Li Li

    Department of Endocrinology, The First Affiliated Hospital of Ningbo University, Ningbo, China

    7 shared publications
  • Yuancheng Dai

    Department of Internal Medicine of Traditional Chinese Medicine, Sheyang Diabetes Hospital, Yancheng, China

    7 shared publications
  • Bangqun Ji

    Department of Endocrinology Xingyi People's Hospital Xingyi China

    6 shared publications

Latest Publications

  • Association of GLP-1RA discontinuation and risk of depressive and anxiety disorders in people with type 2 diabetes: a cohort study

    by Tingyu Zhang, Ping He, Yunxi Ji, Juan Shi, Zizheng Zhang, Kan Wang, Haolei Pan, Huayan Yao, Yanbin Xue, Ruizhi Zheng, et al.

    The psychiatric safety profile of glucagon-like peptide-1 receptor agonists (GLP-1RAs) is characterized by inconsistent findings during active treatment and remains largely unexplored after cessation. Here we show that GLP-1RA discontinuation is associated with an increased risk of psychiatric events. Using large-scale electronic health records from the Shanghai Hospital Link Database, we investigate incident depressive and anxiety disorders during GLP-1RA treatment and after its discontinuation in people with type 2 diabetes, compared with dipeptidyl peptidase-4 inhibitors (DPP4is) or sodium–glucose cotransporter-2 inhibitors (SGLT2is). During treatment, GLP-1RAs show a neutral risk compared with DPP4is and a lower risk compared with SGLT2is. In contrast, after cessation, prior use of GLP-1RAs is associated with a higher risk than prior use of DPP4is or SGLT2is. This increase is modestly mediated by elevated triglyceride levels. These findings highlight the need for clinical vigilance regarding anxiety following GLP-1RA discontinuation.


  • Open Access

    A machine learning model for optimizing treatment of patients with poorly controlled type 2 diabetes

    by Juan Shi, Cong Liu, Jiahang Hu, Yuancheng Dai, Ying Peng, Fengmei Xu, Haonan Shi, Yunsong Li, Jun Li, Zunhai Zhou, et al.

    Background Cardiorenal-protective sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) lack selection guidance. We aimed to build a SGLT-2i/GLP-1RA Decision Score (TiP DecScore) to tailor selection between them. Methods We developed the TiP DecScore in type 2 diabetes (T2D) patients receiving either therapy from the China Metabolic Analytics Project (derivation dataset: n = 24,322; validation dataset: n = 1,459), using gradient boosting decision tree and 15 features. The primary outcomes were glycated haemoglobin (HbA1c) control (1c levels at 6 and 12 months. The model’s clinical effectiveness was evaluated by comparing HbA1c control between concordant (receiving the predicted optimal therapy) and discordant groups (receiving the predicted non-optimal therapy). Results Here we show the derivation cohort has mean (SD) age 53.7 (11.5) years, 63.0% males. Model validation shows good predictive performance (the receiver operating characteristic curve 0.71-0.78). GLP-1RA is favored over SGLT-2i (57.6% vs. 24.2% at 6 months; 57.9% vs. 28.6% at 12 months). At 6 months, compared with SGLT-2i, GLP-1RA is prioritized for patients with a shorter diabetes duration and higher fasting C-peptide, alanine aminotransferase, body mass index (BMI), and low-density lipoprotein cholesterol levels. At 12 months, patients with higher baseline HbA1c and BMI levels are more likely to be recommended GLP-1RA than SGLT-2i. Higher rates of HbA1c control are observed in concordant versus discordant groups, especially in younger patients (<55 years; 64.1% vs. 46.2%, P = 0.001) and males (58.6% vs. 45.6%, P = 0.018) at 12 months. Conclusions The TiP DecScore effectively guides personalized selection between SGLT-2i and GLP-1RA therapies for T2D patients.


  • Open Access

    Sleep Phenotypes, Genetic Susceptibility, and Risk of Obesity in Patients With Type 2 Diabetes: A National Prospective Cohort Study

    by Lei Xi, Li Li, Songbo Fu, Yuancheng Dai, Juan Shi, Yanmei Yu, Ying Peng, Hongmei Qiu, Jinsong Kuang, Hongyun Lu, et al.

    Background: To determine the associations between sleep phenotypes and the risks of specific obesity types and weight gain in patients with type 2 diabetes (T2D), especially in different genetic risk groups.Materials and Methods: We conducted a prospective study involving 58 890 participants. Sleep and napping were assessed according to the standardized questionnaire. General and abdominal obesity were defined by BMI or visceral fat area (VFA), respectively. Multivariable Cox regression, stratified, and joint analysis were performed to explore potential correlations. Furthermore, mediation models were constructed to figure out the mediating role of metabolic factors (blood pressure, UACR, and HbA1c).Results: During a median 3.05‐year follow‐up period, short sleep increased the risk of obesity (HR 1.42, 95% CI 1.17–1.71; 1.33, 1.08–1.65) and weight gain (1.21, 1.09–1.34; 1.17, 1.06–1.29), while long sleep and napping were unrelated to abdominal obesity and weight gain. Mediation analysis showed that systolic blood pressure, UACR, and HbA1c mediated the statistical association between night sleep duration and general obesity with proportions (%) of 7.9, 1.8, and 8.8, respectively. Joint analysis showed both sleep and napping groups had no significance among the low genetic risk group, while long napping, short sleep, and long sleep increased the risk of general obesity in medium to high risk patients.Conclusions: Short sleep, long sleep, and long napping increased the risk of general obesity and BMI‐defined weight gain, and were more pronounced in the medium to high genetic risk group. Napping was unrelated to abdominal obesity. Metabolic factors partially explain the mechanism between sleep and obesity.


  • Open Access

    Association of visceral fat area or BMI with arterial stiffness in ideal cardiovascular health metrics among T2DM patients

    by Ling Zhao, Xiangming Zhou, Yufei Chen, Qijuan Dong, Qidong Zheng, Yufan Wang, Li Li, Dong Zhao, Bangqun Ji, Fengmei Xu, et al.

    Background: “Obesity paradox” occurs in type 2 diabetes mellitus (T2DM) patients when body mass index (BMI) is applied to define obesity. We examined the association of visceral fat area (VFA) as an obesity measurement with arterial stiffness in seven ideal cardiovascular health metrics (ICVHMs).Methods: A total of 29 048 patients were included in the analysis from June 2017 to April 2021 in 10 sites of National Metabolic Management Centers. ICVHMs were modified from the recommendations of the American Heart Association. Brachial‐ankle pulse wave velocity (BaPWV) ≥ 1400 cm/s was employed to evaluate increased arterial stiffness. Multivariate regression models were used to compare the different effects of BMI and VFA on arterial stiffness.Results: Lower VFA was more strongly associated with low BaPWV than lower BMI when other ICVHMs were included (adjusted odds ratio [OR], 0.85 [95% confidence interval [CI], 0.80–0.90] vs OR 1.08 [95% CI, 1.00–1.17]). Multivariable‐adjusted ORs for arterial stiffness were highest in patients with the VAT area VFA in the range of 150‐200 cm2 (adjusted OR, 1.26 [95% CI 1.12–1.41]). Compared with participants with VAT VFA < 100 cm2, among participants with higher VAT VFA, the OR for arterial stiffness decreased gradually from 1.89 (95% CI, 1.73–2.07) in patients who had ≤1 ICVHM to 0.39 (95% CI, 0.25–0.62) in patients who had ≥5 ICVHMs.Conclusion: In patients with T2DM, using VAT for anthropometric measures of obesity, VFA was more relevant to cardiovascular risk than BMI in the seven ICVHMs. For anthropometric measures of obesity in the ICVHMs to describe cardiovascular risk VFA would be more optimal than BMI.


  • Open Access

    The effects of economic status on metabolic control in type 2 diabetes mellitus at 10 metabolic management centers in China

    by Liping Gu, Yuhang Ma, Qidong Zheng, Weiqiong Gu, Tingyu Ke, Li Li, Dong Zhao, Yuancheng Dai, Qijuan Dong, Bangqun Ji, et al.

    Objective: This study investigated the association of economic status with metabolic index control in type 2 diabetes mellitus (T2DM) patients.Methods: In total, 37 454 T2DM patients from 10 National Metabolic Management Centers in China were recruited and categorized into two groups: a high‐gross domestic product (GDP) group (n = 23 993) and a low‐GDP group (n = 13 461). Sociodemographic characteristics, medical histories, and lifestyle factors were recorded. Logistic regression and interaction analysis were performed to evaluate the association of economic status and healthy lifestyle with metabolic control.Results: Compared to the low‐GDP group, there were fewer patients with glycated hemoglobin (HbA1c) levels ≥7% in the high‐GDP group. Fewer patients with a high GDP had an abnormal metabolic state (HbA1c ≥ 7%, blood pressure [BP] ≥130/80 mm Hg, total cholesterol [TCH] ≥4.5 mmol/L or body mass index [BMI] ≥24 kg/m2). The risks of developing HbA1c ≥ 7% (odds ratios [OR] = 0.545 [95% CI: 0.515–0.577], p < .001), BP ≥ 130/80 mm Hg (OR = 0.808 [95% CI: 0.770–0.849], p < .001), BMI ≥ 24 kg/m2 (OR = 0.840 [95% CI: 0.799–0.884], p < .001), and an abnormal metabolic state (OR = 0.533 [95% CI: 0.444–0.636], p < .001) were significantly lower in the high‐GDP group even after adjustment for confounding factors. Younger participants; those with a family history of diabetes, normal weight, and a physical activity level up to standard; and those who did not drink alcohol in the high‐GDP group were predisposed to better glycemic levels.Conclusions: T2DM patients in economically developed regions had better metabolic control, especially glycemic control. A healthy lifestyle had an additive effect on achieving glycemic goals, even among high‐GDP patients.


  • Open Access

    Follow‐up frequency and clinical outcomes in patients with type 2 diabetes: A prospective analysis based on multicenter real‐world data

    by Qiubo Zhao, Hongwei Li, Qicheng Ni, Yuancheng Dai, Qidong Zheng, Yufan Wang, Tingyu Ke, Li Li, Dong Zhao, Qijuan Dong, et al.

    Background: To determine whether the follow‐up frequency for type 2 diabetes mellitus (T2DM) patients in the National Metabolic Management Centers (MMCs) leads to different clinical outcomes.Methods: A total of 19 908 T2DM patients with at least 6 months of facility‐based follow‐up were recruited in MMCs between June 2017 and April 2021 and divided into lower‐frequency and higher‐frequency follow‐up (LFF and HFF) groups according to the median follow‐up frequency of 2.0 (interquartile range 1.2) times per year. Metabolic parameters at baseline and at the last follow‐up visit were analyzed. Multivariable linear regression models were performed to assess the relationship between follow‐up frequency and between‐group percentage changes, adjusting for the major covariables. Additional stratified analyses were conducted to evaluate the metabolic outcomes in the subgroups.Results: The characteristics of the participants in the LFF and HFF groups were significantly different at baseline. Participants had significant improvements in multiple metabolic parameters after follow‐up. Patients with HFF showed significantly greater decrease in percentage changes of fasting blood glucose (−4.95% ± 37.96% vs −2.21% ± 43.08%, P < .0001) and glycosylated hemoglobin (HbA1c) (−12.14% ± 19.78% vs −9.67% ± 20.29%, P < .0001) after adjustments compared to those with LFF. Furthermore, stratification analyses showed that significant between‐group percentage changes of HbA1c were observed in those with younger age (9%) at baseline (P for interaction <.001).Conclusions: HFF is associated with better metabolic outcomes. Participants, especially with younger age or worse HbA1c at baseline in the HFF group achieved better glycemic control than those in the LFF group.


  • Open Access

    Kidney disease parameters, metabolic goal achievement, and arterial stiffness risk in Chinese adult people with type 2 diabetes

    by Chen Xu, Li Li, Juan Shi, Bangqun Ji, Qidong Zheng, Yufan Wang, Tingyu Ke, Dong Zhao, Yuancheng Dai, Fengmei Xu, et al.

    Background: To investigate the arterial stiffness (AS) risk within urinary albumin‐to‐creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) categories and the joint effect between kidney disease parameters and metabolic goal achievement on AS risk in adult people with type 2 diabetes (T2D).Methods: A total of 27 439 Chinese participants with T2D from 10 National Metabolic Management Centers (MMC) were categorized into four albuminuria/decreased eGFR groups. The criteria for decreased eGFR and AS were eGFR the 75th percentile (1770.0 cm/s). Three metabolic goals were defined as glycated hemoglobin p = .311). When the metabolic goals added up to ≥2 for patients with decreased eGFR, they showed significantly lower AS risk (OR: 0.65; 95% CI: 0.56–0.74; p < .001).Conclusions: Both higher UACR and lower eGFR are determinants of AS risk, with UACR more strongly related to AS than eGFR in adults with T2D. The correlation between albuminuria/decreased eGFR and AS was modified by the achievement of multiple metabolic elements.


  • Open Access

    Effects of basal and premixed insulin on glycemic control in type 2 diabetes patients based on multicenter prospective real‐world data

    by Ying Peng, Peihong Xu, Juan Shi, Yifei Zhang, Shujie Wang, Qidong Zheng, Yufan Wang, Tingyu Ke, Li Li, Dong Zhao, et al.

    Background: To investigate the different efficacies of glycemic control between basal and premixed insulin in participants with type 2 diabetes (T2DM) when non‐insulin medications fail to reach treatment targets.Methods: This was a prospective, large‐scale, real‐world study at 10 diabetes centers in China. Between June 2017 and June 2021, we enrolled 1104 T2DM participants initiated with either once‐daily basal insulin or twice‐daily premixed insulin when the glycosylated hemoglobin (HbA1c) control target was not met after at least two non‐insulin agents were administered. A Cox proportional hazards regression model adjusting for multiple influencing factors was performed to compare the different effects of basal and premixed insulin on reaching the HbA1c control target.Results: At baseline, basal insulin (57.3%) was prescribed more frequently than premixed insulin (42.7%). Patients with a higher body mass index (BMI) or higher HbA1c levels were more likely to receive premixed insulin than basal insulin (both p < 0.001). After a median follow‐up of 12.0 months, compared to those with premixed insulin, the hazard ratio for reaching the HbA1c target to those with basal insulin was 1.10 (95% CI, 0.92‐1.31; p = 0.29) after adjustment, and less weight gain was observed in those with basal insulin than with premixed insulin (percentage change of BMI from baseline −0.37[5.50]% vs 3.40[6.73]%, p < 0.0001).Conclusions: In this real‐world study, once‐daily basal insulin was more frequently prescribed and had similar glycemic control effects but less weight gain compared with twice‐daily premixed insulin when used as initiation therapy for those in whom glycemic control with non‐insulin medications failed.